Salvinorin A: the 'magic mint' hallucinogen finds a molecular target in the kappa opioid receptor

被引：119

作者：

Sheffler, DJ

Roth, BL

机构：

[1] Case Western Reserve Univ, Sch Med, Natl Inst Mental Hlth, Psychoact Drug Screening Program, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA

[3] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA

[4] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2003年 / 24卷 / 03期

关键词：

D O I：

10.1016/S0165-6147(03)00027-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Salvinorin A, a neoclerodane diterpene, is the most potent naturally occurring hallucinogen known and rivals the synthetic hallucinogen lysergic acid diethylamide in potency. Recently, the molecular target of salvinorin A was identified as the kappa opioid receptor (KOR). Salvinorin A represents the only known non-nitrogenous KOR selective agonist. Based on the selectivity of salvinorin A for the KOR, this receptor represents a potential molecular target for the development of drugs to treat disorders characterized by alterations in perception, including schizophrenia, Alzheimer's disease and bipolar disorder.

引用

页码：107 / 109

页数：3

共 50 条

[1] Molecular interactions of salvinorin a at the kappa opioid receptor.
Kane, BE
McCurdy, CR
Ferguson, DM
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U57 - U57
[2] Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents
Walentiny, D. Matthew
Vann, Robert E.
Warner, Jonathan A.
King, Lindsey S.
Seltzman, Herbert H.
Navarro, Hernan A.
Twine, Charles E., Jr.
Thomas, Brian F.
Gilliam, Anne F.
Gilmour, Brian P.
Carroll, F. Ivy
Wiley, Jenny L.
PSYCHOPHARMACOLOGY, 2010, 210 (02) : 275 - 284
[3] Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents
D. Matthew Walentiny
Robert E. Vann
Jonathan A. Warner
Lindsey S. King
Herbert H. Seltzman
Hernán A. Navarro
Charles E. Twine
Brian F. Thomas
Anne F. Gilliam
Brian P. Gilmour
F. Ivy Carroll
Jenny L. Wiley
Psychopharmacology, 2010, 210 : 275 - 284
[4] Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
Butelman, Eduardo R.
Kreek, Mary Jeanne
FRONTIERS IN PHARMACOLOGY, 2015, 6
[5] Opioid Receptor Probes Derived from Cycloaddition of the Hallucinogen Natural Product Salvinorin A
Lozama, Anthony
Cunningham, Christopher W.
Caspers, Michael J.
Douglas, Justin T.
Dersch, Christina M.
Rothman, Richard B.
Prisinzano, Thomas E.
JOURNAL OF NATURAL PRODUCTS, 2011, 74 (04): : 718 - 726
[6] Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse
Fantegrossi, WE
Kugle, KM
Valdes, LJ
Koreeda, M
Woods, JH
BEHAVIOURAL PHARMACOLOGY, 2005, 16 (08): : 627 - 633
[7] A review of salvinorin analogs and their kappa-opioid receptor activity
Roach, Jeremy J.
Shenvi, Ryan A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (09) : 1436 - 1445
[8] Importance of homology modeling template selection: CXCR4-based model of the kappa-opioid receptor with the novel hallucinogen salvinorin A
Mosier, Philip D.
Koparde, Vishal N.
Westkaemper, Richard B.
Roth, Bryan L.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[9] PSYCHOTOMIMETIC EFFECTS OF THE KAPPA OPIOID RECEPTOR AGONIST SALVINORIN A IN HEALTHY HUMANS
Ranganathan, Mohini
D'Souza, D.
SCHIZOPHRENIA BULLETIN, 2009, 35 : 338 - 338
[10] Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum
Johnson, Matthew W.
MacLean, Katherine A.
Reissig, Chad J.
Prisinzano, Thomas E.
Griffiths, Roland R.
DRUG AND ALCOHOL DEPENDENCE, 2011, 115 (1-2) : 150 - 155

← 1 2 3 4 5 →